Clinical Trial Update: Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study [Phase 1]

View source ↗

Summary

Phase I study evaluating adjunctive methylene blue for immunotherapy-related cytokine release syndrome and ICANS; recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Immune Effector Cell Associated Neurotoxicity Syndrome

Drugs mentioned

• METHYLENE BLUE (METHYLENE BLUE)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Cytokine Release Syndrome, ICANS | Phase 1 | Status: RECRUITING